We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+0.73%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+632.23%
AUM
$24.1B
AUM Growth
+$1.97B
(+8.9%)
Cap. Flow
+$2.04B
Cap. Flow
% of AUM
8.47%
Top 10 Holdings %
Top 10 Hldgs %
10.49%
Holding
3,709
New
1,117
Increased
953
Reduced
622
Closed
747
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Uber
UBER
|
+$127M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$126M |
| 3 |
Canadian Pacific Kansas City
CP
|
+$122M |
| 4 |
SkinHealth Systems
SKIN
|
+$90.5M |
| 5 |
Advanced Micro Devices
AMD
|
+$81.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$210M |
| 2 |
PARA
Paramount Global Class B
PARA
|
+$187M |
| 3 |
XYZ
Block Inc
XYZ
|
+$111M |
| 4 |
Danaher
DHR
|
+$109M |
| 5 |
Monster Beverage
MNST
|
+$101M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.28% |
| 2 | Financials | 16.56% |
| 3 | Technology | 13.74% |
| 4 | Consumer Discretionary | 11.01% |
| 5 | Communication Services | 4.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMDX
2751
Insight Molecular Diagnostics
IMDX
$143M
| $225K | ﹤0.01% |
3,161
-3,775
| -54% | -$347K |
|
2752
PTC Therapeutics
PTCT
$6.15B
| $225K | ﹤0.01% |
6,042
| – | – |
|
|
MBTC
2753
DELISTED
Nocturne Acquisition Corporation Ordinary Shares
MBTC
| $225K | ﹤0.01% |
+22,522
| New | +$223K |
|
2754
LSI Industries
LYTS
$907M
| $224K | ﹤0.01% |
28,939
-99,726
| -78% | -$760K |
|
2755
RxSight
RXST
$293M
| $224K | ﹤0.01% |
+17,705
| New | +$244K |
|
2756
iShares MSCI Peru and Global Exposure ETF
EPU
$552M
| $223K | ﹤0.01% |
+8,456
| New | +$229K |
|
2757
LGI Homes
LGIH
$1.34B
| $223K | ﹤0.01% |
+1,570
| New | +$248K |
|
2758
Urban One Class D
UONEK
$23.7M
| $223K | ﹤0.01% |
+3,277
| New | +$189K |
|
2759
Lightpath Technologies
LPTH
$822M
| $222K | ﹤0.01% |
104,263
-84,521
| -45% | -$187K |
|
2760
Syndax Pharmaceuticals
SNDX
$1.81B
| $222K | ﹤0.01% |
+11,637
| New | +$194K |
|
2761
Hooker Furnishings Corp
HOFT
$163M
| $221K | ﹤0.01% |
8,204
-9,040
| -52% | -$289K |
|
2762
Establishment Labs
ESTA
$2.21B
| $220K | ﹤0.01% |
+3,073
| New | +$226K |
|
2763
iShares MSCI Global Metals & Mining Producers ETF
PICK
$2.33B
| $220K | ﹤0.01% |
5,400
-18,759
| -78% | -$843K |
|
2764
Red Robin
RRGB
$145M
| $220K | ﹤0.01% |
+9,551
| New | +$246K |
|
2765
Church & Dwight Co
CHD
$24.4B
| $219K | ﹤0.01% |
+2,649
| New | +$225K |
|
2766
Calix
CALX
$2.49B
| $218K | ﹤0.01% |
+4,414
| New | +$204K |
|
|
GOOS
2767
Canada Goose Holdings
GOOS
$856M
| $218K | ﹤0.01% |
+6,100
| New | +$243K |
|
2768
Corsair Gaming
CRSR
$1.39B
| $217K | ﹤0.01% |
+8,377
| New | +$240K |
|
|
IVC
2769
DELISTED
Invacare Corporation
IVC
| $217K | ﹤0.01% |
+45,582
| New | +$333K |
|
2770
Liquidity Services
LQDT
$1.31B
| $216K | ﹤0.01% |
+9,991
| New | +$228K |
|
2771
Atlanticus Holdings
ATLC
$1.42B
| $215K | ﹤0.01% |
+4,049
| New | +$198K |
|
2772
Cibus
CBUS
$145M
| $215K | ﹤0.01% |
1,270
+328
| +35% | +$63.5K |
|
2773
Dana Inc
DAN
$3.27B
| $213K | ﹤0.01% |
+9,597
| New | +$221K |
|
2774
PUT
Cleveland-Cliffs
CLF
$7.08B
| $212K | ﹤0.01% |
10,700
-178,600
| -94% | -$4.07M |
|
2775
Paysafe
PSFE
$353M
| $211K | ﹤0.01% |
2,267
-40,875
| -95% | -$4.68M |
|
Similar funds
Marshall Wace's Q3 2021 Portfolio in Review
As of Q3 2021, Marshall Wace held 3,709 positions worth $24.1B, up 8.9% from $22.1B the previous quarter. Its ten largest holdings account for 10% of the portfolio.
Marshall Wace deployed $2.04B of net new capital in Q3 2021, opening 1,117 new positions and adding to 953 existing holdings. Its largest new stake was SkinHealth Systems: 4,113,430 shares worth $107M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Biogen, an estimated $210M trimmed.
- Marshall Wace's largest Q3 2021 buy was SkinHealth Systems: 4,113,430 shares worth $107M.
- Marshall Wace added most to Uber in Q3 2021, an estimated $127M increase.
- Marshall Wace's biggest Q3 2021 reduction was Biogen, cutting an estimated $210M.
- Marshall Wace fully exited Vipshop in Q3 2021, selling an estimated $58.7M.
- Marshall Wace's ten largest holdings make up 10% of its $24.1B portfolio in Q3 2021.
- Marshall Wace opened 1,117 new positions and closed 747 in Q3 2021.
- Marshall Wace's portfolio value rose 8.9% quarter-over-quarter to $24.1B.
Based on Marshall Wace's 13F filing for Q3 2021, filed 15 Nov 2021.